المؤلفون: Zeverijn LJ; Netherlands Cancer Institute, Amsterdam, Netherlands., Geurts BS; Netherlands Cancer Institute, Netherlands., Battaglia TW; Netherlands Cancer Institute, Amsterdam, Netherlands., van Berge Henegouwen JM; Erasmus MC, Rotterdam, Netherlands., de Wit GF; Netherlands Cancer Institute, Amsterdam, Netherlands., Hoes LR; Netherlands Cancer Institute, Amsterdam, Netherlands., van der Wijngaart H; Maastricht University Medical Centre, Netherlands., van der Noort V; Netherlands Cancer Institute, Amsterdam, Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, Netherlands., de Leng WWJ; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands., Jansen AML; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands., Chalabi M; Netherlands Cancer Institute, Amsterdam, Netherlands., van Herpen CML; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands., Devriese LA; University Medical Center Utrecht Cancer Center, Utrecht, Netherlands., Erdkamp FLG; Zuyderland Medisch Centrum, Netherlands., Labots M; Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, Netherlands., de Jonge MJA; Erasmus MC Cancer Institute, Rotterdam, Netherlands., Kerver ED; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands., Bins AD; Amsterdam UMC, Amsterdam, Netherlands., Leek LVM; Netherlands Cancer Institute, Amsterdam, Netherlands., Notohardjo JCL; Amsterdam UMC Location VUmc, Amsterdam, Netherlands., van den Eertwegh AJM; Amsterdam UMC, Netherlands., Wessels LFA; The Netherlands Cancer Institute, Amsterdam, NH, Netherlands., Verheul HMW; Erasmus MC, Rotterdam, Netherlands., Gelderblom H; Leiden University Medical Center, Leiden, Netherlands., van de Haar J; The Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., Voest EE; Netherlands Cancer Institute, Amsterdam, Netherlands.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jul 18. Date of Electronic Publication: 2024 Jul 18.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

المؤلفون: Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van Berge Henegouwen JM; Department of Clinical Genetics, Erasmus Medical Center, Leiden, The Netherlands., van der Wijngaart H; Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, The Netherlands., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Spiekman IA; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Battaglia TW; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van Beek DM; Hartwig Medical Foundation, Amsterdam, The Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., Jansen AM; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., de Leng WW; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Labots M; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., van Herpen CM; Department of Medical Oncology, Radboud Medical Center, Nijmegen, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.

المصدر: The Journal of pathology [J Pathol] 2024 Jul; Vol. 263 (3), pp. 288-299. Date of Electronic Publication: 2024 May 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley And Sons Country of Publication: England NLM ID: 0204634 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9896 (Electronic) Linking ISSN: 00223417 NLM ISO Abbreviation: J Pathol Subsets: MEDLINE

مواضيع طبية MeSH: Microsatellite Instability* , DNA Mismatch Repair* , Immune Checkpoint Inhibitors*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Aged ; Immunotherapy/methods ; Whole Genome Sequencing ; Adult ; Biomarkers, Tumor/genetics ; Neoplasms/genetics ; Neoplasms/therapy ; Neoplasms/pathology ; Aged, 80 and over ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/therapy

المؤلفون: Battaglia TW; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Mimpen IL; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Traets JJH; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., van Hoeck A; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Department of Head and Neck Surgery and Oncology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Geurts BS; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Noë M; Department of Pathology, Antoni van Leeuwenhoek/the Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Vos JL; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cornelissen S; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Alkemade M; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Zuur CL; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Department of Head and Neck Surgery and Oncology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Department of Otorhinolaryngology Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands., Cuppen E; Center for Molecular Medicine, University Medical Centre Utrecht, Utrecht 3584CX, the Netherlands; Hartwig Medical Foundation, Science Park, Amsterdam 1098XH, the Netherlands., Wessels L; Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Faculty of EEMCS, Delft University of Technology, Delft 2628 CD, the Netherlands., van de Haar J; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Voest E; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. Electronic address: e.voest@nki.nl.

المصدر: Cell [Cell] 2024 Apr 25; Vol. 187 (9), pp. 2324-2335.e19. Date of Electronic Publication: 2024 Apr 09.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 0413066 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4172 (Electronic) Linking ISSN: 00928674 NLM ISO Abbreviation: Cell Subsets: MEDLINE

مواضيع طبية MeSH: Microbiota* , Neoplasm Metastasis* , Neoplasms*/microbiology , Neoplasms*/pathology, Humans ; Metagenomics/methods ; Lung Neoplasms/microbiology ; Lung Neoplasms/pathology ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/pharmacology ; Neutrophils/immunology ; Tumor Microenvironment ; Bacteria/genetics ; Bacteria/classification

المؤلفون: Frijlink E; Division of Tumor Biology and Immunology and Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, Netherlands., Bosma DM; Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, Netherlands., Busselaar J; Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, Netherlands., Battaglia TW; Division of Molecular Oncology and Immunology and Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., Staal MD; Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, Netherlands., Verbrugge I; Division of Tumor Biology and Immunology and Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., Borst J; Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, Netherlands.

المصدر: The Journal of clinical investigation [J Clin Invest] 2024 Feb 13; Vol. 134 (6). Date of Electronic Publication: 2024 Feb 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

مواضيع طبية MeSH: CD28 Antigens* , Neoplasms*, Animals ; Humans ; Mice ; B7-1 Antigen/genetics ; B7-H1 Antigen ; CTLA-4 Antigen/genetics ; Disease Models, Animal ; Programmed Cell Death 1 Receptor/genetics ; T-Lymphocytes, Regulatory

المؤلفون: Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Battaglia TW; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van Berge Henegouwen JM; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van der Wijngaart H; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centre, location VUMC, Amsterdam, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., de Leng WWJ; Department of Pathology, University Medical Cancer Centre Utrecht, Utrecht, the Netherlands., Jansen AML; Department of Pathology, University Medical Cancer Centre Utrecht, Utrecht, the Netherlands., Opdam FL; Department of Clinical Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., de Jonge MJA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Cirkel GA; Department of Medical Oncology, Meander, Amersfoort, the Netherlands., Labots M; Department of Medical Oncology, Amsterdam University Medical Centre, location VUMC, Amsterdam, the Netherlands., Hoeben A; Department of Medical Oncology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands., Kerver ED; Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands., Bins AD; Department of Medical Oncology, Amsterdam University Medical Centre, location AUMC, Amsterdam, the Netherlands., Erdkamp FGL; Department of Medical Oncology, Zuyderland Hospital, Sittard-Geelen, the Netherlands., van Rooijen JM; Department of Medical Oncology, Martini Hospital, Groningen, the Netherlands., Houtsma D; Department of Medical Oncology, Haga Hospital, The Hague, the Netherlands., Hendriks MP; Department of Medical Oncology, Northwest Clinics, Alkmaar, the Netherlands., de Groot JB; Department of Medical Oncology, Isala, Zwolle, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.; Oncode Institute, Utrecht, the Netherlands. e.voest@nki.nl.

المصدر: BMC cancer [BMC Cancer] 2023 Mar 04; Vol. 23 (1), pp. 205. Date of Electronic Publication: 2023 Mar 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Microsatellite Instability* , Brain Neoplasms*, Humans ; Biomarkers

SCR Disease Name: Turcot syndrome

المؤلفون: de Vries NL; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., Veninga V; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Chalabi M; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Ijsselsteijn ME; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., van der Ploeg M; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., van den Bulk J; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Ruano D; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., van den Berg JG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JB; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Zeverijn LJ; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Geurts BS; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., de Wit GF; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Battaglia TW; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands., Schumacher TN; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Wessels LFA; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Faculty of EEMCS, Delft University of Technology, Delft, The Netherlands., Koning F; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., de Miranda NFCC; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. n.f.de_miranda@lumc.nl., Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. e.voest@nki.nl.; Oncode Institute, Utrecht, The Netherlands. e.voest@nki.nl.

المصدر: Nature [Nature] 2023 Jan; Vol. 613 (7945), pp. 743-750. Date of Electronic Publication: 2023 Jan 11.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE

مواضيع طبية MeSH: Colonic Neoplasms*/drug therapy , Colonic Neoplasms*/genetics , Colonic Neoplasms*/immunology , Colonic Neoplasms*/therapy , Histocompatibility Antigens Class I*/genetics , Histocompatibility Antigens Class I*/immunology , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use , Immunotherapy* , Receptors, Antigen, T-Cell, gamma-delta*/immunology , T-Lymphocytes*/immunology , Genes, MHC Class I*/genetics, Humans ; beta 2-Microglobulin/deficiency ; beta 2-Microglobulin/genetics ; DNA Mismatch Repair/genetics ; Receptors, KIR ; Cell Line, Tumor ; Organoids ; Antigen Presentation

SCR Disease Name: Turcot syndrome

المؤلفون: Liu M; NYU Langone Health, New York, United States.; Vilcek Institute of Graduate Biomedical Sciences, New York, United States., Devlin JC; NYU Langone Health, New York, United States.; Vilcek Institute of Graduate Biomedical Sciences, New York, United States., Hu J; NYU Langone Health, New York, United States., Volkova A; NYU Langone Health, New York, United States.; Vilcek Institute of Graduate Biomedical Sciences, New York, United States., Battaglia TW; NYU Langone Health, New York, United States., Ho M; NYU Langone Health, New York, United States., Asplin JR; Litholink Corporation, Laboratory Corporation of America Holdings, Chicago, United States., Byrd A; Department of Cancer Immunology, Genentech Inc, South San Francisco, United States., Loke P; NYU Langone Health, New York, United States., Li H; NYU Langone Health, New York, United States., Ruggles KV; NYU Langone Health, New York, United States., Tsirigos A; NYU Langone Health, New York, United States., Blaser MJ; Center for Advanced Biotechnology and Medicine, Rutgers University, New York, United States., Nazzal L; NYU Langone Health, New York, United States.

المصدر: ELife [Elife] 2021 Mar 26; Vol. 10. Date of Electronic Publication: 2021 Mar 26.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE

مواضيع طبية MeSH: Gastrointestinal Microbiome*, Bacteria/*metabolism , Inflammatory Bowel Diseases/*metabolism , Oxalates/*metabolism , Oxalobacter formigenes/*physiology, Animals ; Feces/chemistry ; Homeostasis ; Humans ; Inflammatory Bowel Diseases/microbiology ; Male ; Mice ; Mice, Inbred C57BL ; Oxalates/urine

المؤلفون: Roubaud-Baudron C; CHU Bordeaux, Pôle de Gérontologie Clinique, Bordeaux, France.; University of Bordeaux, INSERM, UMR1053 Bordeaux Research in Translational Oncology, BaRITOn, Bordeaux, France.; Department of Medicine, New York University Langone Medical Center, New York, New York, USA., Ruiz VE; Department of Medicine, New York University Langone Medical Center, New York, New York, USA.; Department of Biology, St. Francis College, Brooklyn, New York, USA., Swan AM Jr; Department of Medicine, New York University Langone Medical Center, New York, New York, USA., Vallance BA; Division of Gastroenterology, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada., Ozkul C; Department of Medicine, New York University Langone Medical Center, New York, New York, USA.; Department of Pharmaceutical Microbiology, Hacettepe University School of Pharmacy, Ankara, Turkey., Pei Z; Department of Pathology, New York University Langone Medical Center, New York, New York, USA., Li J; Department of Medicine, New York University Langone Medical Center, New York, New York, USA., Battaglia TW; Department of Medicine, New York University Langone Medical Center, New York, New York, USA., Perez-Perez GI; Department of Medicine, New York University Langone Medical Center, New York, New York, USA., Blaser MJ; Department of Medicine, New York University Langone Medical Center, New York, New York, USA Martin.Blaser@cabm.rutgers.edu.; Center for Advanced Biotechnology and Medicine, Rutgers University, New Brunswick, NJ, USA.

المصدر: MBio [mBio] 2019 Dec 24; Vol. 10 (6). Date of Electronic Publication: 2019 Dec 24.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 101519231 Publication Model: Electronic Cited Medium: Internet ISSN: 2150-7511 (Electronic) NLM ISO Abbreviation: mBio Subsets: MEDLINE

مواضيع طبية MeSH: Anti-Bacterial Agents/*administration & dosage , Colitis/*chemically induced , Enterobacteriaceae Infections/*microbiology , Gastrointestinal Microbiome/*drug effects , Long Term Adverse Effects/*chemically induced, Age Factors ; Animals ; Citrobacter rodentium/drug effects ; Citrobacter rodentium/pathogenicity ; Colitis/microbiology ; Colon/drug effects ; Colon/microbiology ; Colon/pathology ; Disease Susceptibility/chemically induced ; Female ; Mice, Inbred C57BL